Stocks News

LAST PRICE
145.5800
TODAY'S CHANGE (%)
Trending Down-1.2400 (-0.8446%)

Bid / Lots
145.5700/ 9
Ask / Lots
145.5900/ 5
Open / Previous Close
146.8800 / 146.8200
Day Range
Low 145.2158
High 146.8800
52 Week Range
Low 143.1300
High 175.9700
Volume
3,731,328
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure, from 7:22AM ET on Monday Apr 29, 2024 by Dow Jones
  7:22AM ET on Monday Apr 29, 2024 by Dow Jones
  Companies Mentioned: JNJ, ADXN
  
  By Colin Kellaher
  
  U.S.-listed shares Addex Therapeutics plunged nearly 60% in premarket trading Monday after the clinical-stage biopharmaceutical company reported the failure of a mid-stage study of a proposed epilepsy drug it is developing with Johnson & Johnson.
Apr 26, 2024
- Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment, from 12:29PM ET on Friday Apr 26, 2024 by MT Newswires
  12:29PM ET on Friday Apr 26, 2024 by MT Newswires
  Companies Mentioned: JNJ
  12:29 PM EDT, 04/26/2024 (MT Newswires) -- Johnson & Johnson's (JNJ) Janssen-Cilag International said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Rybrevant (ami...
Apr 25, 2024
- --Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170, from 7:39AM ET on Thursday Apr 25, 2024 by MT Newswires
  7:39AM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: JNJ
  07:39 AM EDT, 04/25/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
Apr 24, 2024
- DJ Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset, from 7:01PM ET on Wednesday Apr 24, 2024 by Dow Jones
  7:01PM ET on Wednesday Apr 24, 2024 by Dow Jones
  Companies Mentioned: JNJ, CDTX
  
  By Ben Glickman
  
  Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates.
  
  The stock was up 42% to $17.50 in after-hours trading, following a 20% jump in Wednesday's regular session. Shares are up roughly 15-fold since the start of the year.
Apr 22, 2024
- Johnson & Johnson to Participate in the Bernstein's 40(th) Annual Strategic Decisions Conference (SDC), from 4:30PM ET on Monday Apr 22, 2024 by Dow Jones
  4:30PM ET on Monday Apr 22, 2024 by Dow Jones
  Companies Mentioned: JNJ
  NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--April 22, 2024--
  Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein's 40(th) Annual Strategic Decisions Conference (SDC) on Wednesday, May 29(th) , at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time).

Today
- Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings, from 2 hours ago by MT Newswires
  2 hours ago by MT Newswires
  Companies Mentioned: ETN, F, GSK, HSBC, HMC, KO, LLY, BBVA, MCD, MSFT, NVO, TSLA, TEVA, TM, GM, WMT, AZN, AMPH, CRVS
- Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 2 hours ago by MT Newswires
  2 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, NVS, TEVA, AZN, AMPH
- FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, NVS, TEVA, AZN, AMPH
- --FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, TEVA, AZN, AMPH
Yesterday
- European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares, from 12:11PM ET on Monday Apr 29, 2024 by MT Newswires
  12:11PM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: META, AZN, SHEL, DB
- BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating, from 11:24AM ET on Monday Apr 29, 2024 by MT Newswires
  11:24AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: ABBV
- AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed, from 10:56AM ET on Monday Apr 29, 2024 by MT Newswires
  10:56AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: AIM, AZN
- AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement, from 10:26AM ET on Monday Apr 29, 2024 by MT Newswires
  10:26AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: AZN
- Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine, from 10:11AM ET on Monday Apr 29, 2024 by MT Newswires
  10:11AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: MRK
- Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, from 9:00AM ET on Monday Apr 29, 2024 by Business Wire
  9:00AM ET on Monday Apr 29, 2024 by Business Wire
  Companies Mentioned: MRK

Johnson & Johnson
NYSE:JNJUnited States

Search Criteria

Yesterday

DJ Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure, from 7:22AM ET on Monday Apr 29, 2024 by Dow Jones

Apr 26, 2024

Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment, from 12:29PM ET on Friday Apr 26, 2024 by MT Newswires

Apr 25, 2024

--Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170, from 7:39AM ET on Thursday Apr 25, 2024 by MT Newswires

Apr 24, 2024

DJ Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset, from 7:01PM ET on Wednesday Apr 24, 2024 by Dow Jones

Apr 22, 2024

Johnson & Johnson to Participate in the Bernstein's 40(th) Annual Strategic Decisions Conference (SDC), from 4:30PM ET on Monday Apr 22, 2024 by Dow Jones

Peers Headlines

Today

Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings, from 2 hours ago by MT Newswires

Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 2 hours ago by MT Newswires

FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 3 hours ago by MT Newswires

--FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 3 hours ago by MT Newswires

Yesterday

European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares, from 12:11PM ET on Monday Apr 29, 2024 by MT Newswires

BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating, from 11:24AM ET on Monday Apr 29, 2024 by MT Newswires

AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed, from 10:56AM ET on Monday Apr 29, 2024 by MT Newswires

AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement, from 10:26AM ET on Monday Apr 29, 2024 by MT Newswires

Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine, from 10:11AM ET on Monday Apr 29, 2024 by MT Newswires

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, from 9:00AM ET on Monday Apr 29, 2024 by Business Wire